Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris
George
G
Augmentium Pharma Consulting, Toronto, Ontario, Canada. george@augmentium.com
Kahn
Susan R
SR
Stumpo
Carmine
C
Paton
Thomas W
TW
Martineau
Josee
J
Smith
Reginald
R
Ginsberg
Jeffrey S
JS
D000925:Anticoagulants / Q000008:administration & dosage / Q000145:classification / Q000191:economics* / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects / Q000191:economics; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects / Q000191:economics; D002170:Canada / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D017984:Enoxaparin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000077425:Fondaparinux; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D017059:Models, Econometric; D019637:Orthopedic Procedures / Q000009:adverse effects; D011134:Polysaccharides / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D011134:Polysaccharides; D000077425:Fondaparinux